These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11956959)

  • 1. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data.
    Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L
    J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL.
    Formichi P; Parnetti L; Radi E; Cevenini G; Dotti MT; Federico A
    Eur J Neurol; 2008 Nov; 15(11):1252-5. PubMed ID: 18803653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
    Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
    JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.
    de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M
    Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.
    Cicognola C; Brinkmalm G; Wahlgren J; Portelius E; Gobom J; Cullen NC; Hansson O; Parnetti L; Constantinescu R; Wildsmith K; Chen HH; Beach TG; Lashley T; Zetterberg H; Blennow K; Höglund K
    Acta Neuropathol; 2019 Feb; 137(2):279-296. PubMed ID: 30547227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.
    Kandimalla RJ; S P; Bk B; Wani WY; Sharma DR; Grover VK; Bhardwaj N; Jain K; Gill KD
    Neurosci Lett; 2011 Jan; 487(2):134-8. PubMed ID: 20599474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease markers in the aged sheep (Ovis aries).
    Reid SJ; Mckean NE; Henty K; Portelius E; Blennow K; Rudiger SR; Bawden CS; Handley RR; Verma PJ; Faull RLM; Waldvogel HJ; Zetterberg H; Snell RG
    Neurobiol Aging; 2017 Oct; 58():112-119. PubMed ID: 28728117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of Alzheimer's disease: the present and the future.
    Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
    Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.
    Braak H; Zetterberg H; Del Tredici K; Blennow K
    Acta Neuropathol; 2013 Nov; 126(5):631-41. PubMed ID: 23756600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.